logo-loader

MediciNova completes first half of phase II trial for MS drug

Last updated: 10:31 13 Jul 2016 EDT, First published: 05:31 13 Jul 2016 EDT

picture of microscope
Phase II trial is halfway through

MediciNova Inc (NASDAQ:MNOV) has completed half of its phase II trial for ibudilast, its new treatment for multiple sclerosis, 

Out of 255 enrolled patients, 127 have now completed the 96-week treatment period.

The trial’s external Data Safety Monitoring Board will review the results of an interim efficacy analysis in the fourth quarter ahead of making a recommendation to the National Institute of Neurological Diseases and Stroke (NINDS).   

Yuichi Iwaki, MediciNova’s chief executive, said: "We are very pleased to have reached the 50% completion milestone in this important study.

“The unmet medical need for progressive MS patients is extremely high as there is no treatment approved for long-term use for these patients.”

The trial is being carried out across 28 enrolling clinical sites across the US and will evaluate the safety, tolerability and efficacy of MN-166 (ibudilast) administered twice daily to subjects with primary or secondary progressive multiple sclerosis.

ARway.ai announces multiple new SaaS developer contracts in both the United...

ARway.ai (CSE:ARWY, OTCQB:ARWYF) Chief Executive Officer Evan Gappelberg joined Steve Darling from Proactive to announce multiple new SaaS developer sign-ups for its augmented reality experience platform, focusing on AR indoor navigation. These partnerships represent significant milestones in...

45 minutes ago